Trial Profile
Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients: a prospective, observational (non interventional), international, multicentre cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- 29 Jul 2020 Results (N=1484), of a 1-year multicenter observational study in France, published in the Clinical Drug Investigation
- 20 Sep 2016 Interim results (n=625) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.